Skip to main content
. Author manuscript; available in PMC: 2017 Nov 16.
Published in final edited form as: Biomaterials. 2016 Mar 12;93:95–105. doi: 10.1016/j.biomaterials.2016.03.017

Figure 4. All mvsFlt bioconjugates maintain their ability to inhibit VEGF165 dependent activities in VEGF165 ELISA and VEGF165-dependent HUVEC survival assays.

Figure 4

A) Dose-dependent inhibition of VEGF165 binding to a capture antibody by mvsFlt bioconjugates. Inhibition was independent of whether the sFlt was bound to HyA or free in solution. There were no significant differences between any of the groups (Table 3). B) Dose-dependent inhibition of HUVEC survival with mvsFlt at different molecular weights and protein valencies in the presence of VEGF165. Inhibition was independent of whether the sFlt was bound to HyA or free in solution (Table 3). Values are given as means ±SD.